GBC AG: MagForce AG | Rating: Buy
Original-Research: MagForce AG - von GBC AG
Einstufung von GBC AG zu MagForce AG
Unternehmen: MagForce AG
ISIN: DE000A0HGQF5
Anlass der Studie: Research Comment
Empfehlung: Buy
Kursziel: 11.00 EUR
Kursziel auf Sicht von: 31.12.2021
Letzte Ratingänderung:
Analyst: Cosmin Filker, Marcel Goldmann
Further results of the pivotal study 2a confirm expectations, market approval in 2021 still in prospect, price target of EUR 11.00 and BUY rating confirmed
After MagForce AG announced the successful completion of stage 2a of the pivotal study for the treatment of prostate cancer in the USA in February 2021, the company has published additional, more concrete results on this study phase in a recent company announcement. After further analysis of the results of the 10 patients included in phase 2a, only minimal side effects were observed in the streamlined treatment procedure, thus once again confirming the good safety and tolerability profile.
However, the data on the efficacy of prostate treatment with MagForce technology are also very encouraging, according to the company. Very welldefined ablation and cell death in the area of the nanoparticle depot were observed. In treatment with MagForce technology, magnetic nanoparticles are introduced directly into the tumor and then heated, thereby destroying the cancer cells. The pivotal study 2a demonstrated that the minimally invasive procedure developed in phase 1 allows the nanoparticles to be introduced very precisely and to remain in the desired location. Ablation in the target area was very precise and there was minimal damage to the surrounding tissue (range 2-4 mm).
The promising data form a good basis for the Phase 2b registration trial, which is due to start shortly and in which patient recruitment is at an advanced stage. In this final part of the study, which is necessary for approval, the efficacy and safety of the MagForce technology in the treatment of prostate cancer will be demonstrated in a total of up to 100 men. This will take place at a total of three centers in the USA, in Texas, Washington and Florida. The inclusion of three treatment centers is intended to ensure a prompt readiness for operation following approval. As before, the study is expected to be completed in the second half of 2021. This is also against the backdrop of the streamlined treatment procedure developed during the approval phase 2a, which currently comprises only one day. In addition, MagForce management does not currently identify any further material pandemic delays to the further progress of the U.S. trial.
MagForce AG's current corporate announcement should be regarded as a confirmation of the results already available. There is no relevant information that would influence our revenue and earnings forecasts, which is why we are keeping them unchanged. We continue to expect that revenue from the prostate cancer treatment business should increase significantly from 2022 onwards. In the current fiscal year 2021, the company should therefore generate revenues primarily from the treatment of glio-blastoma, which has already been approved in Europe. The EBITDA break-even should be reached from 2022.
We therefore maintain both our forecasts and our price target of EUR11.00 per share. At a share price of EUR4.06, we continue to assign a BUY rating.
Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/22380.pdf
Kontakt für Rückfragen
Jörg Grunwald
Vorstand
GBC AG
Halderstraße 27
86150 Augsburg
0821 / 241133 0
research@gbc-ag.de
++++++++++++++++
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG und Art. 20 MAR. Beim oben analysierten Unternehmen ist folgender möglicher Interessenkonflikt gegeben: (5a,11); Einen Katalog möglicher Interessenkonflikte finden Sie unter:
http://www.gbc-ag.de/de/Offenlegung
+++++++++++++++
Date (time) of completion: 29/04/2021 (12:35)
Date (Time) first distribution: 29/04/2021 (02:00 pm)
-------------------übermittelt durch die EQS Group AG.-------------------
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
